Gilead Sciences, Inc. (Nasdaq: GILD) has agreed to buy CV Therapeutics, Inc. (Nasdaq: CVTX) for $20.00 per share in cash. (more...) ... Read Full Story »
CV Therapeutics, Inc. (NASDAQ: CVTX) is seeing a surge in its shares this morning. It looks like CV is the next biotech merger target now that Astellas Pharma Inc. submitted ... Read Full Story »
These are some of the top analyst downgrades we have seen this Friday morning:Americredit (ACF) Raised to Market Perform at FBR.Cliff’s Natural resources (CLF) Cut to Market Perform at FBR.CV ... Read Full Story »
If you thought biotech news was getting quiet going into earnings season, think again.Acadia Pharmaceuticals Inc. (ACAD) presents Phase II data on pimavanserin, a treatment for Parkinson’s disease psychosis (PDP) ... Read Full Story »
CV Therapeutics, Inc. (NASDAQ: CVTX) has secured a deal with TPG-Axon Capital, where it will receive up to $185 million in exchange for the rights to 50% of CV Therapeutics' ... Read Full Story »
Alkermes (NASDAQ: ALKS) and Johnson & Johnson Pharmaceutical Research and Developed today submitted paperwork seeking approval of their partnership drug, RISPERDAL CONSTA, to be allowed for treatment of bipolar disorder ... Read Full Story »
Dycom Industries (DY) Posts loss on lawsuit settlement. Falls to $11.88 from 52-week high of $34.13.Nortel (NT) Big loss and lay-offs. Down to $9.67 from 52-week high of $30.27.Journal Register ... Read Full Story »
Posted by Thomas Catino Ant&SonsShares of CV Therapeutics Inc. (CVTX) are slumping, down $.60, or 5.52%, to $10.26 on moderate volume. It's been a volatile ride for the stock that ... Read Full Story »
(AA) Alcoa $0.81 EPS vs $0.81e; will likely have to sweeten Alcan bid before getting any approval from Alcan.(BOT) CBOT holders approve the CME merger offer.(CACS) Carrier Access lowered guidance.(CAKE) ... Read Full Story »
(AA) An ALCOA bid from BHP may be kindled according to numerous M&A reports.(ADVNA) Advanta trades ex-split to reflect a 3-2 stock split.(AGU) Agrium said earnings will be at or ... Read Full Story »
On tonight's Mad Money on CNBC, Jim Cramer had his normal 'Speculation Friday' and talked CV Therapeutics (CVTX) for a speculative biotech in with Acadia (ACAD) and Nastech (NSTK). Cramer ... Read Full Story »